Document Detail


Intravenous aminobisphosphonate in Paget's disease: clinical, biochemical, histomorphometric and radiological responses.
MedLine Citation:
PMID:  2036728     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Intravenous 3-amino-1-hydroxypropylidene-1, 1-bisphosphonic acid (APD) was used to treat 26 patients with Paget's disease. Three daily dosages were studied; 20-30 mg/day in 20 patients, 45 mg/day in three patients and 60 mg/day in three patients, by daily 4-hour infusions for 2-10 days. The fasting urinary hydroxyproline excretion (HypE) declined exponentially, reaching 50% of pretreatment values at 1.92 +/- 0.16 (mean +/- SEM) days. This initial rapid decline was complete by 4 days following treatment to a mean of 28.0 +/- 3.4% of pretreatment values. Thereafter, there was no significant decline in HypE. The initial rate of decline of HypE was unchanged by increasing the daily dose of APD. Transient non-symptomatic hypocalcaemia with secondary hyperparathyroidism occurred in all patients. No adverse changes in the renal handling of calcium or phosphate, as seen with high-dose 1-hydroxyethylidene-1, 1-bisphosphonate (EHDP), were seen in any patient on any daily dose. Fever occurred in 73% of patients in the first 2 days of treatment. Overall, there was a significant fall in the lymphocyte count (P less than 0.005 febrile group, n = 19; P less than 0.02 non-febrile group, n = 7) and a fever-dependent rise in the neutrophil count (P less than 0.005 febrile group only). The occurrence of fever was associated with a more rapid decline in HypE, compared to the non-febrile group, so that HypE was significantly lower in the febrile group by day 5 (P less than 0.025). Seventy-two per cent of patients with bone and/or joint pain reported a reduction in pain.(ABSTRACT TRUNCATED AT 250 WORDS)
Authors:
A J Fenton; D H Gutteridge; G N Kent; R I Price; R W Retallack; C I Bhagat; G K Worth; R I Thompson; I G Watson; C Barry-Walsh
Related Documents :
17722968 - Safety considerations with bisphosphonates for the treatment of osteoporosis.
19401368 - Effects of teriparatide retreatment in osteoporotic men and women.
23412308 - A comparison of biomechanical changes on femoral head following rotational acetabular o...
15824848 - Intravenous neridronate in children with osteogenesis imperfecta: a randomized controll...
11552918 - Outcomes of helicobacter pylori treatment in community practice and impact of therapeut...
23108638 - Sports hernia in national hockey league players: does surgery affect performance?
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical endocrinology     Volume:  34     ISSN:  0300-0664     ISO Abbreviation:  Clin. Endocrinol. (Oxf)     Publication Date:  1991 Mar 
Date Detail:
Created Date:  1991-06-28     Completed Date:  1991-06-28     Revised Date:  2006-03-08    
Medline Journal Info:
Nlm Unique ID:  0346653     Medline TA:  Clin Endocrinol (Oxf)     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  197-204     Citation Subset:  IM    
Affiliation:
Department of Endocrinology, Sir Charles Gairdner Hospital, Nedlands, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Bone and Bones / pathology
Diphosphonates / administration & dosage,  adverse effects,  therapeutic use*
Drug Administration Schedule
Female
Humans
Hydroxyproline / urine
Infusions, Intravenous
Leukocyte Count / drug effects
Male
Middle Aged
Osteitis Deformans / drug therapy*,  metabolism,  pathology,  radiography
Chemical
Reg. No./Substance:
0/Diphosphonates; 40391-99-9/pamidronate; 51-35-4/Hydroxyproline

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Growth hormone, insulin-like growth factor I, insulin and C-peptide during human fetal life: in-uter...
Next Document:  Effect of growth hormone therapy on thyroid status of girls with Turner's syndrome.